non-familial hypercholesterolaemia with ASCVD
Cardiovascular · 2018–2020
4decisions
2medicines
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alirocumab Non-familial hypercholesterolaemia (non-FH) in patients with atherosclerotic cardiovascular disease (ASCVD) and additional high-risk factors. | Mar 2020 | Recommended with restriction | none received |
| evolocumab Treatment of non-familial hypercholesterolaemia in patients with atherosclerotic cardiovascular disease who have additional risk factors, and extension of… | Jul 2019 | Deferred | 2 individuals |
| evolocumab Treatment of non-familial hypercholesterolaemia in patients with atherosclerotic cardiovascular disease and additional high-risk factors, and extension of… | Nov 2019 | Recommended with restriction | none received |
| evolocumab Treatment of non-familial hypercholesterolaemia with atherosclerotic cardiovascular disease in patients who have not achieved target LDL levels despite… | Jul 2018 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.